Nolan Garry Ph.D.'s Form 4 filing
Akoya Biosciences, Inc. (AKYA) · filed Sep 13, 2022
- Accession no.
- 0001104659-22-099627
- Filed
- Sep 13, 2022
- Trade date
- Sep 9-12, 2022
- Filing delay
- 4 days
- Rule 10b5-1 plan
- Not on the form (before 2023)
This filing lists 2 non-derivative transactions and 0 derivative transactions. Open-market sales total $319.3K. It was filed 4 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Nolan Garry Ph.D.CIK 0001857405 | Director |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Sep 9, 2022 | Common Stock | SSaleDisposed | −22,191 | $13.31 | −$295,362.21 | 632,893 | Direct | |
| Sep 12, 2022 | Common Stock | SSaleDisposed | −1,800 | $13.30 | −$23,940 | 631,093 | Direct |
Footnotes
Livermore does not store Form 4 footnotes. For price ranges, how indirect holdings are held and trading plan details, read the original on SEC EDGAR.